- Home
- CAN vs SLDB Comparison
CAN vs SLDB Comparison
Compare CAN & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | SLDB |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.0M | 498.6M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CAN | SLDB |
|---|---|---|
| Price | $0.48 | $6.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $3.09 | ★ $14.70 |
| AVG Volume (30 Days) | ★ 19.7M | 1.1M |
| Earning Date | 02-10-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $529,735,000.00 | N/A |
| Revenue This Year | $36.73 | N/A |
| Revenue Next Year | $27.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.69 | N/A |
| 52 Week Low | $0.47 | $2.41 |
| 52 Week High | $2.22 | $7.37 |
Technical Indicators
Market Signals| Indicator | CAN | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 49.86 |
| Support Level | $0.50 | $6.01 |
| Resistance Level | $0.63 | $7.33 |
| Average True Range (ATR) | 0.05 | 0.43 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 6.19 | 31.48 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.